Overexpression of NEDD9 in renal cell carcinoma is associated with tumor migration and invasion

Wang, Jue; Wang, Si; Luan, Yun; Zhang, Wenhua; Sun, Chao; Cheng, Guanghui; Li, Kailin; Xin, Qian; Lin, Zhao‐Min; Qi, Tonggang; Kong, Feng

doi:10.3892/ol.2017.7231

Cited by 7 publications

(9 citation statements)

References 24 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…NEDD9 overexpression was reported in 1309 (52.9%) of the 2476 included patients. Amongst all study cohorts, 3 evaluated lung cancer,23,27,33 4 assessed gastric cancer,28,30,32,39 3 undertook urinary bladder carcinoma,31,34,36 2 illustrated pancreatic carcinoma,29,38 and single studies focused on breast cancer,25 colorectal cancer,24 hepatocellular carcinoma,26 renal carcinoma,37 melanoma,35 and ovarian cancer 8. Studies were conducted in China (11), Japan (1), Turkey (3), Croatia (1), and Egypt (2).…”

Section: Resultsmentioning

confidence: 99%

See 1 more Smart Citation

<p>NEDD9 overexpression predicts poor prognosis in solid cancers: a meta-analysis</p>

Lü

Chen

et al. 2019

OTT

View full text Add to dashboard Cite

Background: The oncogenicity of neural precursor cell-expressed developmentally down-regulated 9 (NEDD9) has been demonstrated in multiple cancer types. However, the prognostic value of NEDD9 in some solid cancers remains controversial. Thus, this meta-analysis was conducted to evaluate the relationship between NEDD9 expression survival rates in solid tumors. Method: Our meta-analysis included studies searched from various search engines with specific inclusion criteria and exclusion criteria. Combined HRs for overall survival (OS) and disease-free survival (DFS) or progression-free survival (PFS) or recurrence-free survival (RFS) or cancer-specific survival (CSS) were assessed using fixed-effects and random-effects models. The source of heterogeneity was identified by subgroup analysis. Additionally, publication bias was assessed using funnel plot and Egger’s regression asymmetry test. Result: Eighteen studies with a total of 2,476 patients were retrieved for analysis. Pooled HRs and 95% CIs were calculated. Both OS (HR=1.82; 95% CI: 1.43–2.31) and DFS/PFS/RFS/CSS (HR=2.54; 95% CI: 1.93–3.33) indicated that NEDD9 overexpression is associated with poor OS in cancer patients with solid tumors. Conclusion: NEDD9 overexpression might be a potential marker to predict prognosis in solid cancer patients.

show abstract

Section: Resultsmentioning

confidence: 99%

“…The combined HR estimate was 2.54 (95% CI: 1.93–3.33; P =0.142), which indicated that NEDD9 overexpression was associated with poor DFS/PFS/RFS/CSS (Figure 3). The studies were subdivided by cancer location: digestive system (n=2),32,38 respiratory system (n=1),23 breast and ovarian cancer (n=2),8,25 and urinary system cancer (n=2) 36,37…”

Section: Resultsmentioning

confidence: 99%

<p>NEDD9 overexpression predicts poor prognosis in solid cancers: a meta-analysis</p>

Lü

Chen

et al. 2019

OTT

View full text Add to dashboard Cite

show abstract

“…NEDD9 depletion destabilizes AURKA and heightens the efficacy of Aurora A inhibitors and it has implications for treatment of metastatic solid tumors [19]. NEDD9 has been found to be diagnostic, prognostic, and predictive in different kinds of tumor types [12,20,21,22].…”

Section: Discussionmentioning

confidence: 99%

“…Neural precursor cell expressed developmentally downregulated protein 9 (NEDD9) was initially identified by its developmentally regulated expression pattern in early embryonic, but not adult, mouse brain [8]. Overexpression of NEDD9 protein has now been strongly linked to poor prognosis in various types of cancers, as well as resistance to first-line chemotherapeutics [9,10,11,12,13,14]. There are few articles in the literature about the association of NEDD9 and PC [15,16,17].…”

Section: Introductionmentioning

confidence: 99%

Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer

Afşar

Karabulut

et al. 2018

Biomolecules

View full text Add to dashboard Cite

Introduction: Pancreatic cancer (PC) is a lethal malignancy. Various diagnostic, predictive, and prognostic biomarkers have been evaluated. This study was conducted to investigate the serum levels of neural precursor cell expressed developmentally downregulated protein 9 (NEDD9) in patients with PC and the relationship between tumor progression and known prognostic parameters. Materials and Methods: Serum samples were obtained on first admission before any treatment. Serum NEDD9 levels were determined using enzyme-linked immunosorbent assay (ELISA). Age- and sex-matched healthy controls were included in the analysis. Results: In a three year period, 32 patients with a pathologically-confirmed diagnosis of PC were enrolled in this study. The median age at diagnosis was 61 years, range 38 to 84 years; the majority of the patients in the group were men (n = 20, 62.5%). The tumor was located in the head of pancreas in 21 (65.6%) patients. Forty-one percent of 17 metastatic patients who received palliative CTx (chemotherapy) were CTx-responsive. The baseline serum NEDD9 levels were significantly higher in patients with PA than in the control group (p = 0.03). Median OS of the whole group were 27 ± 7.3 weeks. Alcohol intake, performance status, and LDH levels were found to be significant prognostic factors (p = 0.006, p < 0.001, and p < 0.001, respectively). However, serum NEDD9 levels had no significantly effect on progression free survival (PFS) and overall survival (OS) (p = 0.71 and p = 0.58, respectively). Conclusions: NEDD9 is identified as a secretory biomarker for PC but it has no prognostic role.

show abstract

“…Due to its pleotropic functions (cell adhesion, migration, invasion and EMT), the elevated expression of NEDD9 has emerged as a predictor of poor outcome, metastatic potential and chemoresistence in multiple cancer types (breast cancer, gastric cancer, glioblastoma, head and neck squamous cell carcinoma, hepatocellular carcinoma, non-small cell lung cancer, ovarian cancer, renal cancer, pancreatic ductal adenocarcinoma, prostate cancer and T-cell leukemia) (10–19). NEDD9 is a bona fide melanoma metastasis gene that enhances invasion in vitro and metastasis in vivo of both normal and transformed melanocytes (14).…”

Section: Introductionmentioning

confidence: 99%

E‑cadherin and NEDD9 expression in primary colorectal cancer, metastatic lymph nodes and liver metastases

Jurčić¹,

Radulović

Balja

et al. 2019

Oncol Lett

View full text Add to dashboard Cite

In Croatia, colorectal cancer mortality rates in males are the third highest in Europe, after Hungary and Slovakia. The results for females rank Croatia in second place after Hungary. According to previous studies, the loss of E-cadherin expression and the higher expression of neural precursor cell-expressed developmentally downregulated 9 (NEDD9) are associated with a worse prognosis. The aim of the present study was to analyze the immunohistochemical expression of NEDD9 and E-cadherin as markers of metastatic potential using a tissue microarray. This retrospective study included 40 previously untreated patients, including 23 males and 17 females with a median age of 64.5 years (range 38–84), with colorectal cancer and synchronous liver metastases that underwent simultaneous colorectal and hepatic resection between January 1st 2006 and December 31st 2013, in the Clinical Hospital Center Sestre Milosrdnice (Zagreb, Croatia). The most frequent tumor stage was T3, while the most frequent nodal stage was N1. Microvascular invasion was present in 37.5% of patients, while perineural invasion was observed in 30% of patients. The immunohistochemical staining index of E-cadherin was highly positive in 87.5% samples of colorectal cancer, 67.7% of lymph nodes and 77.5% of liver metastases. In the primary tumor, highly positive NEDD9 expression was identified in 22.5% of patients. In lymph nodes, it was identified in 35.5% of patients, while in the liver, it was identified in 30% of patients. Significant positive correlations were observed between the percentage of positive lymph nodes and the immunohistochemical staining index of E-cadherin (ρ=0.372; P=0.039) and NEDD9 (ρ=0.451; P=0.011) in lymph nodes. After the conclusion of the study, 55% of the patients succumbed. No significant differences in survival rates were identified regarding the expression of E-cadherin and NEDD9 in the primary tumor, metastatic lymph nodes and liver metastases. Due to the small sample size and the negative results obtained, further research is required to implement these parameters as prognostic factors.

show abstract

Overexpression of NEDD9 in renal cell carcinoma is associated with tumor migration and invasion

Cited by 7 publications

References 24 publications

<p>NEDD9 overexpression predicts poor prognosis in solid cancers: a meta-analysis</p>

<p>NEDD9 overexpression predicts poor prognosis in solid cancers: a meta-analysis</p>

Clinical Significance of Serum NEDD9 Levels in Patients with Pancreatic Cancer

E‑cadherin and NEDD9 expression in primary colorectal cancer, metastatic lymph nodes and liver metastases

Contact Info

Product

Resources

About